-

Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of Inotiv, Inc. (NOTV) Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV). The investigation concerns whether Inotiv has violated the federal securities laws and/or engaged in other unlawful business practices.

Inotiv provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries.

On May 20, 2022, Inotiv disclosed that, after executing a search and seizure warrant at one of the Company’s facilities, the U.S. Department of Justice filed a complaint alleging violations of the Animal Welfare Act at Inotiv’s Cumberland, Virginia facility. On this news, the price of Inotiv stock declined by $5.19 per share, or approximately 28.3%, from $18.33 per share to close at $13.14 per share on May 23, 2022.

If you purchased or otherwise acquired Inotiv securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:NOTV

Release Versions

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

BIODESIX, INC. BDSX INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 57% Share Drop

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Biodesix, Inc. (“Biodesix” or the “Company”) (NASDAQ: BDSX) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM’S INVESTIGATION]What Happened?On November 5, 2026, Biodesix announced its third quarter 2026 financial results, reporting third quarte...

CVRX INVESTORS: Contact Kirby McInerney LLP About the Securities Fraud Lawsuit Filed on Behalf of CVRx, Inc. Shareholders

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds investors who purchased CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below by January 8, 2027, to discuss your rights or interests in the securities fraud class action at no cost.[CONTACT THE FIRM IF YOU SUFFERED A LOSS]What Is The Lawsuit About?The lawsuit has been filed on behalf of investors who purchased...

ABR INVESTORS: Contact Kirby McInerney LLP About the Securities Fraud Lawsuit Filed on Behalf of Arbor Realty Trust, Inc. Shareholders

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds investors who purchased Arbor Realty Trust, Inc. (“Arbor Realty” or the “Company”) (NYSE: ABR) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below by January 8, 2027, to discuss your rights or interests in the securities fraud class action at no cost.[CONTACT THE FIRM IF YOU SUFFERED A LOSS]What Is The Lawsuit About?The lawsuit has been filed on behalf of inves...
Back to Newsroom